close× Call Us 1(844) 401-0111

Recent Memory and Aging Program News

See the latest news about Butler Hospital's Memory & Aging Program and how they are working towards a future without Alzheimer's disease through clinical research studies.


Newsweek – “The New Offensive on Alzheimer’s Disease: Stop It Before It Starts”—In a recently published comprehensive article, Newsweek took stock of the current state of affairs for Alzheimer’s disease (AD). The cover story for the February 24 edition, the article delves into the far-reaching effects and implications of the disease, including how it will continue to wreak havoc on the global community, both from a health and wellness perspective, as well as financially. Though finding a cure for AD has held a prominent focus in the research and pharmaceutical fields, the clinical trials testing treatments for AD have a more than 99 percent failure rate. Currently, researchers have switched their attention to investigating preventions, with one new prevention study called EARLY, administering a targeted drug to people who are healthy but have elevated amyloid in their brains, which indicates an increased risk of developing AD.

Facing Dementia


Facing Dementia is a five part television series airing on Channel NewsAsia, an English Language TV news channel based in Singapore. The series follows several families as they navigate through diagnosis, caregiving and treatment of loved ones affected by different types of dementia. In this episode, What the Future Holds, Dr. Stephen Salloway discusses the current and future state of Alzheimer’s research as scientists worldwide work together to find a cure. We’re also introduced to two families from the Memory and Aging Program that are participating in different clinical trials, but that have similar goals of slowing down or preventing Alzheimer’s disease.


Washington University School of Medicine in St. Louis - “Landmark Alzheimer’s prevention trial to evaluate third drug” The Washington University School of Medicine in St. Louis is collaborating with Janssen Research & Development to bring a third investigational drug into worldwide clinical trial testing that could potentially be used as a treatment in preventing Alzheimer’s disease. It will become part of a trio of investigational drugs used in the Dominantly Inherited Alzheimer’s Network Trial Unit (DIAN-TU) study. Dr. Stephen Salloway is a Project Arm Leader for DIAN-TU, which is being conducted at Butler’s Memory and Aging Program.


The Providence Journal - "In war on Alzheimer's, R.I.'s Butler Hospital is leading the charge" – This feature story first seen on the front page of the journal, looks at the current affairs in the war on Alzheimer’s disease, and ranks Dr. Stephen Salloway, director of Butler’s Memory and Aging Program, as a general. The in-depth coverage includes articles and accompanying photos and videos that delve into the variety of efforts of Butler’s Memory and Aging Program. A broad spectrum of clinical trials and initiatives that bring the program into collaborations both locally and globally, speak to the committed effort within the Memory and Aging Program to lead a charge toward finding effective treatments for Alzheimer’s.

Also reported by:

The Providence Journal EDITORIAL“Editorial: R.I. battles Alzheimer's”

NBC Channel 10“Health Check: Alzheimer's disease treatment”

ABC Channel 6“A breakthrough clinical trial, giving hope to patients with Alzheimer's”

TIME - "An Alzheimer’s Drug Shows Serious Promise”

Science News“New Alzheimer’s drug shows promise in small trial”

Huffington Post“New Drug Clears Abnormal Brain Proteins Tied To Alzheimer’s”

Fox News“Drug shows promise in reducing abnormal brain proteins linked to Alzheimer’s”

Brown University“Rhode Island’s role in promising new Alzheimer’s results”

Scientific American“Alzheimer's Drug Shows Promise in Small Trial”

Science“Alzheimer’s trial supports β amyloid origin of disease”

Toronto Star"High hopes new drug could be a ‘game changer’ against long-incurable Alzheimer’s”

W Radio (en español)“Fármaco para el Alzhéimer va a estar disponible a la venta en unos años: Stephen Salloway”

 08/11/16 - "Coming to a Center New You: GAP & EPAD to Revamp Alzheimer’s Trials" - This three-part story discusses how two of the largest Alzheimer’s disease (AD) reform initiatives, GAP & EPAD, are leading the worldwide effort to revamp how clinical trials recruit potential participants and the plan to evaluate more AD investigational drugs in a more timely and cost effective manner. Their integrated approach is focused on streamlining communication and procedures among pharmaceutical companies, academics and even individual governments.


The Today Show - "New Alzheimer’s Disease Drug May Help People at Risk" Dr. Reisa Sperling, lead investigator for the A4 study in Boston, talks with Maria Shriver about how the study is investigating a new drug aimed at preventing people from developing a buildup of amyloid protein in the brain, which is associated with Alzheimer’s disease.


WJAR Channel 10 News - "Alzheimer's disease prevention research" Dr. Stephen Salloway discusses a new partnership with the Brain Health Registry and how it can help direct people to participate in prevention trials, such as GeneMatch, especially if there is a family history of Alzheimer’s like Paul Cote’s family.


WJAR Channel 10 News - "Alzheimer's end-of-life study" One of the program’s most highly altruistic trials, the A16 Autopsy Tau Imaging trial, is currently enrolling with the goal of developing a new diagnostic brain scan.


Convergence RI - "Rhode Island emerges as a key hub of Alzheimer’s research" Dr. Stephen Salloway discusses how public-private collaborations are the future for treating and preventing Alzheimer’s by 2025.


Providence Journal - "Help Defeat Alzheimer's" Butler and Rhode Island Hospitals are leading the state in a nationwide study that aims to delay or prevent Alzheimer’s disease in America’s aging population.


Butler Enrolls First Participant in National Landmark Alzheimer's Study Designed to prevent memory loss, the A4 Study" (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease Study) is seeking to enroll 1,000 healthy adults who are at risk for developing Alzheimer's disease but show no outward signs of the disease. Press release


WJAR Channel 10 News - "Alzheimer's Disease Prevention Trial" NBC’s news affiliate covers the story of Peter Bristol as he becomes the first patient to receive treatment in the A4 Study being conducted at Butler Hospital in partnership with National Institutes of Health (NIH) and Eli Lilly.


Rhode Island Public Radio - "Butler Kicks Off Alzheimer's Prevention Trial" Butler Hospital begins enrollment of a national landmark trial, the A4 Study, that tests a specific drug’s potential to help prevent Alzheimer’s disease.


Deep Brain Stimulation Surgery for Alzheimer's Disease Geraldine Paquin is about to embark on uncharted waters undergoing deep brain stimulation (DBS) for Alzheimer's disease. Learn more DBS for Alzheimer's about from WJAR 10's Barbara Morse Silva on Health Check 10.


New Deep Brain Stimulation Study for Alzheimer's Disease Butler Hospital's Memory & Aging Program, in collaboration with Rhode Island Hospital, is testing deep brain stimulation for Alzheimer's disease.